2018
DOI: 10.3171/2018.6.focus18228
|View full text |Cite
|
Sign up to set email alerts
|

Single and staged laser interstitial thermal therapy ablation for cortical tubers causing refractory epilepsy in pediatric patients

Abstract: OBJECTIVEMagnetic resonance–guided laser interstitial thermal therapy (MRgLITT) is a novel, minimally invasive treatment for the surgical treatment of epilepsy. In this paper, the authors report on clinical outcomes for a series of pediatric patients with tuberous sclerosis complex (TSC) and medication-refractory epileptogenic cortical tubers.METHODSA retrospective chart review was performed at SUNY Upstat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
29
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 36 publications
(29 citation statements)
references
References 41 publications
0
29
0
Order By: Relevance
“…These procedures have included dentatolysis, fornicotomy, thalamotomy, hypothalamotomy, amygdalotomy and many others [136][137][138]. Today, stereotactic ablative techniques are used for limited conditions: arteriovenous and cavernous malformations, HHs, mesial temporal lobe sclerosis and, to a lesser extent, complex and deep focal cortical dysplasias, nodular periventricular heterotopias, tuberous sclerosis [139] and subependymal giant cell astrocytomas [140]. Favorable reports exist also for stereoelectroencephalography-guided surgery of neocortical nonlesional epilepsy [10].…”
Section: Drug-resistant Epilepsymentioning
confidence: 99%
“…These procedures have included dentatolysis, fornicotomy, thalamotomy, hypothalamotomy, amygdalotomy and many others [136][137][138]. Today, stereotactic ablative techniques are used for limited conditions: arteriovenous and cavernous malformations, HHs, mesial temporal lobe sclerosis and, to a lesser extent, complex and deep focal cortical dysplasias, nodular periventricular heterotopias, tuberous sclerosis [139] and subependymal giant cell astrocytomas [140]. Favorable reports exist also for stereoelectroencephalography-guided surgery of neocortical nonlesional epilepsy [10].…”
Section: Drug-resistant Epilepsymentioning
confidence: 99%
“…This feature makes LITT an attractive option for treating a variety of small focal lesions that cause epilepsy, such as focal cortical dysplasia (FCD), tuberous sclerosis complex, and periventricular tumors such as subependymal giant cell astrocytoma (SEGA). 6,16,17,41,62 The hypothalamic hamartoma (HH) is one such stereotypical deep-seated epileptogenic lesion. Given the deepseated location and the morbidity of an open procedure, some institutions have begun using LITT as first-line therapy for HH.…”
Section: Litt For Lesionsmentioning
confidence: 99%
“…The best evidence supporting the efficacy of LITT to treat patients with epilepsy with curative intent comes from the ablation of structurally well‐defined targets, including hypothalamic hamartoma and mesial temporal sclerosis 19‐21 . As experience increases, LITT is also being used to treat a growing list of epileptogenic substrates, including focal cortical dysplasia (FCD), cavernous malformation, and lesions in challenging anatomic locations such as the insula and functionally eloquent cortex 22‐24 . This increasing list of pathologies treated with LITT contrasts with the fact that there is no class I evidence comparing the efficacy and complication rates of LITT with those of standard surgical treatment.…”
Section: Introductionmentioning
confidence: 99%
“…These advantages have led to the proliferation of LITT to treat a broad range of epileptic conditions, many of which have yet to generate sufficient evidence to determine efficacy. This includes hemispheric disconnections such as corpus callosotomy using multiple lasers, 36 lesional and nonlesional focal epilepsy in deep and functionally eloquent anatomic locations such as the insula, 37 and focal and multifocal epilepsy in patients with cavernous malformation 38 or tuberous sclerosis complex 24 …”
Section: Introductionmentioning
confidence: 99%